Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has co...
May 27, 2025, 4:10 PM EDT - 2 months ago
May 20, 2025, 4:22 PM EDT - 2 months ago
Apr 15, 2025, 8:00 AM EDT - 3 months ago
Mar 3, 2025, 7:30 AM EST - 5 months ago
Feb 12, 2025, 7:00 AM EST - 5 months ago
Dec 23, 2024, 4:49 PM EST - 7 months ago